

## **ADMISSION TROPONIN-I PREDICTS SUBSEQUENT CARDIAC COMPLICATIONS AND MORTALITY IN ACUTE STROKE PATIENTS**

Alejandro Bustamante, MD (1); Belén Díaz-Fernández, MD (2); Jorge Pagola, MD, PhD (2); Albert Blanco-Grau (3); Marta Rubiera, MD, PhD (2); Anna Penalba (1); Teresa García-Berrocso, PhD (1); Joan Montaner, MD, PhD (1-2).

1. Neurovascular Research Laboratory, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
2. Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
3. Clinical Biochemistry Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

### **SUPPLEMENTARY MATERIAL**

<b>Index</b>	<b>Page</b>
Supplementary table I. Description of the cardiac complications in the cohort.....	2-3
Supplementary table II. Baseline characteristics of the patients with 90-days follow-up data and univariate analysis for 90-day all-cause mortality.....	4
Supplementary figure I. Comparison between predictive models for mortality, including or not the biomarker hs-Tnl.....	5

**SUPPLEMENTARY TABLE I. DESCRIPTION OF THE CARDIAC COMPLICATIONS IN THE COHORT**

<b>PATIENT</b>	<b>AGE</b>	<b>GENDER</b>	<b>hs-Tnl</b>	<b>Complication</b>	<b>Days from stroke onset</b>	<b>ECG features</b>	<b>Outcome of the cardiac complication</b>	<b>Other complications</b>
1	78	F	5022.5*	ACS (MI)	0	ST-segment elevation	Death (cardiac arrest)	-
2	59	M	2.8	ACS (NSTEMI)	3	Normal	Recovered	-
3	85	M	20.5	AHF (PE)	5	AF-RVR	Recovered	Death by pneumonia
4	67	M	3.9	AHF	2	Sinus Tachycardia	Recovered	Mixed dyspnea
5	44	F	3.5	AHF	1	Normal	Recovered	Mixed dyspnea
6	88	F	16.5*	AHF	5	-	Recovered	Humeral hemorrhage
7	56	M	176.1*	AHF (PE)	1	LVH	Death	-
8	93	M	21.6	AHF	2	-	Death	Mixed dyspnea
9	82	F	17.3*	AHF (PE)	14	AF-NVR	Recovered	-
10	67	F	21.6*	AHF (PE)	8	AF-NVR	Death	Valve thrombus
11	83	M	181.7*	AHF	6	-	Recovered	-
12	87	F	18.5*	AHF (PE)	2	AF-RVR	Death	-
13	87	F	133*	AHF	1	AF-RVR	Death	-
14	82	M	4.7	AHF (PE)	2	-	Death	Mixed dyspnea

hs-TnI: ultrasensitive troponin I; ECG: electrocardiogram; F: female gender; M: male gender; ACS: acute coronary syndrome; MI: myocardial infarction; NSTEMI: non ST-segment elevation myocardial infarction; AHF: acute heart failure; PE: pulmonary edema; AF-RVR: atrial fibrillation with rapid ventricular response; AF-NVR: atrial fibrillation with normal ventricular response; LVH: left ventricular hypertrophy.

\* Denotes elevated hs-TnI according to the reference values of the assay.


**SUPPLEMENTARY TABLE II. BASELINE CHARACTERISTICS OF THE PATIENTS WITH 90-DAYS FOLLOW-UP DATA AND UNIVARIATE ANALYSIS FOR 90-DAY ALL-CAUSE MORTALITY**

	<b>All (N=151)</b>	<b>Death (N=28)</b>	<b>Alive (N=123)</b>	<b>p</b>
<b>Age</b>	80 (67.5-84)	81 (68.5-87)	79 (67-84)	0.035**
<b>Gender (male)</b>	82 (54.3%)	16 (57.1%)	66 (53.7%)	0.738
<b>Arterial hypertension</b>	107 (70.9%)	20 (71.4%)	87 (70.7%)	0.942
<b>Diabetes mellitus</b>	34 (22.5%)	10 (35.7%)	24 (19.5%)	0.064
<b>Dyslipidemia</b>	69 (46.3%)	13 (48.1%)	56 (45.9%)	0.832
<b>Previous stroke</b>	30 (19.9%)	8 (28.6%)	20 (17.9%)	0.201
<b>Previous disability</b>	26 (17.2%)	9 (32.1%)	17 (13.8%)	0.028**
<b>Atrial fibrillation</b>	41 (28.3%)	9 (22%)	32 (27.1%)	0.518
<b>CAD</b>	22 (14.6%)	7 (25%)	15 (12.3%)	0.133
<b>Previous CHF</b>	13 (8.6%)	6 (46.2%)	22 (15.9%)	0.016**
<b>OCSF</b>				0.010**
<b>TACI</b>	50 (36.5%)	16 (59.3%)	34 (30.9%)	
<b>PACI</b>	57 (41.6%)	7 (25.9%)	50 (45.5%)	
<b>POCI</b>	14 (10.2%)	4 (14.8%)	10 (9.1%)	
<b>LACI</b>	16 (11.7%)	0 (0%)	16 (14.5%)	
<b>TOAST</b>				0.259
<b>LAA</b>	29 (19.3%)	5 (17.9%)	24 (19.7%)	
<b>CE</b>	63 (42%)	12 (42.9%)	51 (41.8%)	
<b>LAC</b>	13 (8.7%)	0 (0%)	13 (10.7%)	
<b>UND</b>	42 (28%)	11 (39.3%)	31 (25.4%)	
<b>Other</b>	3 (2%)	0 (0%)	3 (2.5%)	
<b>Laterality (right)</b>	33 (39.8%)	7 (33.3%)	26 (41.9%)	0.486
<b>Baseline NIHSS score</b>	9 (3-14.5)	15 (8-18)	7 (3-12)	<0.0001**
<b>SBP (mmHg)</b>	151.8 ± 32.4	145.9 ± 31	152.8 ± 32.7	0.431
<b>DBP (mmHg)</b>	78 (70-85.5)	70.5 (56.5-82.5)	79 (70-86.5)	0.076
<b>Glycemia (mg/dL)</b>	124 (106-153)	143 (124-179.5)	120 (104-149)	0.238
<b>Creatinine (mg/dL)</b>	0.97 (0.81-1.25)	1.08 (0.82-1.37)	0.95 (0.77-1.14)	0.063
<b>Elevated hs-Tnl</b>	37 (24.5%)	13 (46.6%)	24 (19.5%)	0.003**

Data are expressed as N (%), median (interquartile range) or mean ± standard deviation. CAD: coronary artery disease; CHF: congestive heart failure; OCSF: Oxfordshire Stroke Project classification; TACI: total anterior circulation infarct; PACI: partial anterior circulation infarct; POCI: posterior arterial circulation infarct; LACI: lacunar infarct; TOAST: Trial of Org 10172 in Acute Stroke Treatment; LAA: large artery atherothrombotic; CE: cardioembolic; LAC: lacunar; UND: undetermined; NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-Tnl: ultrasensitive Troponin I.


\*\* denotes p<0.05

**SUPPLEMENTARY FIGURE I. COMPARISON BETWEEN PREDICTIVE MODELS FOR MORTALITY, INCLUDING OR NOT THE BIOMARKER hs-TnI**



**A**

A: comparison of the predictive accuracy (area under the ROC curve) of both models. The continuous line represents the predictive model constructed just with clinical variables (previous congestive heart failure-CHF and baseline National Institutes of Health Stroke Scale-NIHSS), and the discontinuous line represents the predictive model constructed with the previous one plus hs-TnI as a dichotomous variable (normal vs. pathological levels according to manufacturer's instructions, >34.2pg/mL male, >15.6pg/ml female).



**B**

B: integrated discrimination improvement (IDI) index: the bars represent the same models than A (dark bars, clinical model and light bars, the same model plus hs-TnI). The predictive probabilities of events (death within 3 months) or no events for each model are expressed as %. The IDI value [IDI=3.55% (-0.7-7.8), p=0.107] results from the sum of the differences in predictive probabilities for events and no events.